以下部分引用 AI 总结，现阶段 AI 仍然有幻觉。请以内容的原文为准。

数据新鲜度群聊 07-14 ✓卖方 07-14 ✓Wrap 断档15天 ✕News 07-15 ✓X 断档12天 ✕页面生成 07-15

AMGEN

6 atoms · 跨 1 天 · 首见 2026-04-30 · 最近 2026-04-30

三色: 🟦 fact 6 · 🟥 take 0 · stance ▲3/▼0/◆0

来源: X 6

时态: fresh:6

标签: 好数字:5 · 好信源:1

2026-04-30 · Q1 2026 revenue
AMGEN POSTED Q1 2026 REVENUE OF $8.62 BILLION (VS $8.57 BILLION ESTIMATE)
tags: 好数字 · → daily
value: qty=$8.62 billion · date=Q1 2026
2026-04-30 · Q1 2026 adjusted EPS
ADJUSTED EPS OF $5.15 (VS $4.75 FORECAST)
tags: 好数字 · → daily
value: qty=$5.15 · date=Q1 2026
2026-04-30 · Q1 2026 adjusted operating income
ADJUSTED OPERATING INCOME OF $3.72 BILLION (VS $3.62 BILLION CONSENSUS)
tags: 好数字 · → daily
value: qty=$3.72 billion · date=Q1 2026
2026-04-30 · FY adjusted EPS guidance raised
LIFTING ITS FY ADJUSTED EPS GUIDANCE TO $21.70–$23.10 (FROM $21.60–$23.00)
tags: 好数字 · → daily
value: qty=$21.70–$23.10 · date=FY 2026
2026-04-30 · FY revenue outlook raised
FY REVENUE OUTLOOK TO $37.1–$38.5 BILLION (FROM $37.0–$38.4 BILLION)
tags: 好数字 · → daily
value: qty=$37.1–$38.5 billion · date=FY 2026
2026-04-30 · plans to engage with FDA on TAVNEOS
AMGEN MAINTAINS THAT TAVNEOS HAS A FAVORABLE BENEFIT-RISK PROFILE, PLANS TO ENGAGE WITH THE FDA ON THE DRUG, AND ADDED THAT IT COULD REQUEST A HEARING ON THE FDA'S TAVNEOS PROPOSAL.
tags: 好信源 · → daily